Expertise in
41
conditions

Dr. Jeremy S. Kortmansky

Oncology
Smilow Cancer Hospital
35 Park St, 
New Haven, CT 
Offers Telehealth
Expertise in
41
conditions
Smilow Cancer Hospital
35 Park St, 
New Haven, CT 

Overview

Jeremy Kortmansky is an Oncologist practicing medicine in New Haven, Connecticut.

Dr. Kortmansky is highly rated in 41 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Gastrostomy.

He is actively involved in clinical research, co-authoring 20 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in CT

Hospital Affiliations

Yale-New Haven Hospital
Bridgeport Hospital
Greenwich Hospital Association -

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Smilow Cancer Hospital
35 Park St, New Haven, CT 06519
Other Locations
Office
6 Devine St Ste 2C, North Haven, CT 06473

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Phase II, Open-label, Single Arm, Multicenter Study of Encorafenib, Binimetinib Plus Cetuximab in Subjects With Previously Untreated BRAF V600E -Mutant Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: July 16, 2026
Intervention Type: Drug
Study Phase: Phase 2
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: May 20, 2026
Intervention Type: Drug, Other
Study Drugs: Fluorouracil, Irinotecan Hydrochloride, Leucovorin Calcium, Veliparib
Study Phase: Phase 2
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification
Enrollment Status: Completed
Publish Date: February 10, 2026
Intervention Type: Device, Biological, Other, Drug
Study Drugs: Cetuximab, Irinotecan, Pertuzumab, Trastuzumab
Study Phase: Phase 2
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
Enrollment Status: Completed
Publish Date: December 04, 2025
Intervention Type: Drug, Radiation, Biological
Study Phase: Phase 2
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision (PROSPECT)
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Procedure, Other, Drug
Study Phase: Phase 2/Phase 3
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Savolitinib
Study Phase: Phase 2
View 6 Less Clinical Trials

20 Total Publications

A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer.
A Phase 2 study of Savolitinib in Patients with MET Amplified Metastatic Colorectal Cancer.
Journal: Journal of gastrointestinal cancer
Published: December 01, 2024
Similar Doctors
Expertise in
21
conditions
Expertise in
21
conditions
Referral may be required

Radiology And Biomedical Imaging-New Haven-Yale Physicians Building

800 Howard Ave, 
New Haven, CT 
 (0.2 miles away)
203-785-2140
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Francine Foss is an Oncologist practicing medicine in New Haven, Connecticut. She has been practicing medicine for over 44 years. Dr. Foss is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), and Non-Hodgkin Lymphoma.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Smilow Cancer Hospital

35 Park St, 
New Haven, CT 
 (0.1 miles away)
203-200-5864
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Scott Gettinger is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Gettinger is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Yale New Haven Hospital

20 York St, 
New Haven, CT 
 (0.1 miles away)
203-785-7385
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Elena Ratner is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Ratner is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Ovarian Carcinosarcoma, Ovarian Cancer, Endometrial Cancer, Salpingo-Oophorectomy, and Vaginectomy.

Frequently Asked Questions about Dr. Jeremy S. Kortmansky

How do I make an appointment with Dr. Jeremy S. Kortmansky?

You can book an appointment with Dr. Jeremy S. Kortmansky by calling their office at 203-688-4242. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeremy S. Kortmansky a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeremy S. Kortmansky is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeremy S. Kortmansky specialize in?

While Dr. Jeremy S. Kortmansky is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Familial Colorectal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Jeremy S. Kortmansky participate in research or clinical trials?

Yes. Dr. Jeremy S. Kortmansky has published 20 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Jeremy S. Kortmansky's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeremy S. Kortmansky accept my insurance?

Dr. Jeremy S. Kortmansky accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 203-688-4242 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kortmansky's expertise for a condition
ConditionClose
    View All 16 Distinguished Conditions
    View All 25 Advanced Conditions
    View All 79 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile